Table 3 Tumor mutation burden between DDR-mutated BCs and non-DDR-mutated BCs
From: High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas
| Â | DDR mutated | Non-DDR mutated | Total | p Value | ||||
|---|---|---|---|---|---|---|---|---|
# (average) | % (range) | # (average) | % (range) | # (average) | % (range) | |||
# | 13 | Â | 49 | Â | 62 | Â | Â | |
Age | 50.7 | 36–70 | 54.6 | 30–78 | 53.8 | 30–78 | 0.2718 | |
Specimens | Biopsy | 10 | 76.9% | 37 | 75.5% | 47 | 75.8% | Â |
Excision | 1 | 7.7% | 9 | 18.4% | 10 | 16.1% | Â | |
Cytology | 2 | 15.4% | 3 | 6.1% | 5 | 8.1% | Â | |
Locations | primary | 3 | 23.1% | 10 | 20.4% | 13 | 21.0% | NS |
Metastatic | 10 | 76.9% | 39 | 79.6% | 49 | 79.0% | ||
Biomarkers | ER/PR+ | 10 | 76.9% | 25 | 51.0% | 35 | 56.5% | 0.01769 |
HER2+ | 2 | 15.4% | 3 | 6.1% | 5 | 8.1% | ||
TNBC | 1 | 7.7% | 21 | 42.9% | 22 | 35.5% | ||
Histologic types | Ductal, NOS | 11 | 84.6% | 41 | 83.7% | 52 | 83.9% | NS |
Lobular | 1 | 7.7% | 5 | 10.2% | 6 | 9.7% | ||
Metaplastic | 1 | 7.7% | 1 | 2.0% | 2 | 3.2% | ||
Neuroendocrine | 0 | 0.0% | 2 | 4.1% | 2 | 3.2% | ||
TMB | 12.08 | 4–33 | 6.57 | 1–61 | 7.73 | 1–61 | 0.042909 | |
Nuclear grade | 2.5 | 2–3 | 2.4 | 2–3 | 2.5 | 2–3 | NS | |
Tumor infiltrating lymphocytes | 8.8% | 1–25% | 6.6% | 0–60% | 7.1% | 0–60% | NS | |